<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735239</url>
  </required_header>
  <id_info>
    <org_study_id>LUD2015-005</org_study_id>
    <nct_id>NCT02735239</nct_id>
  </id_info>
  <brief_title>Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer</brief_title>
  <official_title>Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Institute for Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in
      combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced
      oesophageal cancer (OC) and with neoadjuvant chemo(radio)therapy before surgery in operable
      OC. The immunotherapy will be given for a 4-week period before starting the standard
      chemo(radio)therapy, continuing durvalumab treatment once the chemotherapy starts. The study
      will include 2 phases, a safety run-in Phase 1 (Cohorts A1 and A2) and an expansion Phase 2
      (Cohorts B, C, C-FLOT, D).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 24, 2016</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects reporting Adverse Events</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects experiencing a dose-limiting toxicity</measure>
    <time_frame>up to 10 weeks after the first dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in laboratory evaluations</measure>
    <time_frame>Screening through 3 months after the last dose of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response by irRECIST</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year Survival Rate in subjects with operable oesophageal cancer</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Durvalumab and standard of care chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 will evaluate the safety of durvalumab alone (Cohort A1) administered before chemotherapy (oxaliplatin + capecitabine) in subjects with metastatic or locally advanced Oesophageal Cancer + Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + tremelimumab and standard of care chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation for Tremelimumab 37.5mg - 75mg + Durvalumab 750mg + Chemotherapy (Cohort A2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recommended combination of doses from Cohort A1 or A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort B are subjects with metastatic/locally advanced Oesophageal Cancer. Subjects in Cohort B will receive the recommended combination dose from Cohort A1 (durvalumab alone administered before chemotherapy (oxaliplatin + capecitabine)) or A2 (Dose-escalation for Tremelimumab 37.5mg - 75mg + Durvalumab 750mg + Chemotherapy) and Chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab, surgery and standard of care chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab 750mg + Chemotherapy (Cohort C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab, surgery, standard of care chemo and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab 750mg + Chemotherapy Radiotherapy (Cohort D)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab, surgery, new standard of care chemotherapy C-FLOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab 750mg + Chemotherapy (Cohort C-FLOT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <arm_group_label>Durvalumab + tremelimumab and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Durvalumab and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Durvalumab, surgery and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Durvalumab, surgery, new standard of care chemotherapy C-FLOT</arm_group_label>
    <arm_group_label>Durvalumab, surgery, standard of care chemo and radiotherapy</arm_group_label>
    <arm_group_label>Recommended combination of doses from Cohort A1 or A2</arm_group_label>
    <other_name>MEDI4736</other_name>
    <other_name>Imfinzi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <arm_group_label>Durvalumab + tremelimumab and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Recommended combination of doses from Cohort A1 or A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>IV administered Chemotherapy</description>
    <arm_group_label>Durvalumab + tremelimumab and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Durvalumab and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Durvalumab, surgery and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Durvalumab, surgery, new standard of care chemotherapy C-FLOT</arm_group_label>
    <arm_group_label>Recommended combination of doses from Cohort A1 or A2</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>orally-administered chemotherapy</description>
    <arm_group_label>Durvalumab + tremelimumab and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Durvalumab and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Durvalumab, surgery and standard of care chemotherapy</arm_group_label>
    <arm_group_label>Recommended combination of doses from Cohort A1 or A2</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Durvalumab, surgery, standard of care chemo and radiotherapy</arm_group_label>
    <other_name>Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV administered Chemotherapy</description>
    <arm_group_label>Durvalumab, surgery, standard of care chemo and radiotherapy</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV administered Chemotherapy</description>
    <arm_group_label>Durvalumab, surgery, standard of care chemo and radiotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil (5-FU)</intervention_name>
    <description>IV administered Chemotherapy</description>
    <arm_group_label>Durvalumab, surgery, new standard of care chemotherapy C-FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>orally-administered chemo-protective agent</description>
    <arm_group_label>Durvalumab, surgery, new standard of care chemotherapy C-FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>IV administered Chemotherapy</description>
    <arm_group_label>Durvalumab, surgery, new standard of care chemotherapy C-FLOT</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological diagnosis of oesophageal or gastrooesophageal cancer and have not
             received prior chemotherapy

               -  Cohorts A and B - metastatic/locally advanced cancer

               -  Cohorts C/C-FLOT and D/D2 - deemed suitable for surgery with curative intent

          2. Anticipated lifespan greater than 4 months

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          4. At the time of day 1 of the study, subjects with brain metastases must be asymptomatic
             for at least 4 weeks and:

               -  at least 8 weeks without tumour progression after any whole brain radiotherapy

               -  at least 4 weeks since craniotomy and resection or stereotactic radiosurgery

               -  at least 3 weeks without new brain metastases as evidenced by MRI/CT

          5. Adequate normal organ and marrow function. Laboratory parameters for vital functions
             should be in the normal range. Laboratory abnormalities that are not clinically
             significant are generally permitted.

          6. Written informed consent obtained from the subject; subject been informed of other
             treatment options, and able to comply with study requirements

          7. Age 18 years or older.

        Exclusion Criteria

          1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site). Previous enrollment in the present study.

          2. Participation in another clinical study with an investigational product during the
             last 4 weeks

          3. Mean QT interval corrected for heart rate (QTc) â‰¥470 ms calculated from 3
             electrocardiograms (ECGs) using Fredericia's Correction

          4. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis)

          5. History of allogeneic organ transplant

          6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active
             bleeding diatheses including any subject known to have evidence of acute or chronic
             hepatitis B, hepatitis C, known immunodeficiency or human immunodeficiency virus
             (HIV), or psychiatric illness/social situations that would limit compliance with study
             requirements or compromise the ability of the subject to give written informed consent

          7. Known history of previous clinical diagnosis of tuberculosis

          8. History of pneumonitis or interstitial lung disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Middleton</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oxford, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oesophageal Cancer</keyword>
  <keyword>Oesophageal adenocarcinoma</keyword>
  <keyword>Oesophageal squamous cell carcinoma</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)</keyword>
  <keyword>Programmed cell death protein 1 (PD-1)</keyword>
  <keyword>Programmed death ligand 1 (PD-L1)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

